Goldenberries have long been a niche curiosity, tucked into specialty produce aisles and health food shops while tomatoes and ...

Scientists are using CRISPR to fast-track the domestication of a wild fruit. For roughly 10,000 years, farming communities ...

The company does possess a lot of potential, with its approved gene-editing treatment Casgevy. Unfortunately, sales from that haven't exactly been soaring, and thus its financial performance has ...

To compete at iGEM, a sort of science Olympics, teens at a Georgia high school set their sights on finding a better way to detect and treat Lyme disease. Their approach uses CRISPR gene editing.

Wondering if CRISPR Therapeutics is still a high risk biotech story or a quietly mispriced opportunity? This breakdown will help you decide whether the current share price makes sense for a long term ...

2023 was the year that CRISPR gene-editing sliced its way out of the lab and into the public consciousness—and American medical system. The Food and Drug Administration recently approved the first ...

In the latest close session, CRISPR Therapeutics AG (CRSP) was down 2.5% at $56.46. The stock's performance was behind the S&P 500's daily gain of 0.46%. On the other hand, the Dow registered a gain ...

CRISPR Therapeutics shares early autoimmune and lymphoma data for zugo-cel, showing strong responses, manageable safety, and ...

A child who received the world's first personalized CRISPR therapy is now taking his first steps after months in hospital ...

CRISPR biosensors enable real-time health monitoring with attomolar sensitivity, wearable integration, and multiplex ...

A miracle baby who was treated with a pioneering gene-therapy at CHOP has reached a major milestone as he took his first ...

Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the 100 ...